Abstract
Clinical pharmacology is the study of drugs in healthy volunteers and patients and defining the relationships between dose, drug exposure, and response in populations. Drug dose refers to an amount of drug administered via a particular dose route (e.g., intravenous, oral, subcutaneous). Drug exposure is a function of the concentration of drug in the body, and usually levels in the blood/plasma/serum serve as a surrogate, with respect to time. Response is a measure of effect and can relate to both advantageous (efficacy) and untoward (toxic) reactions. The dose–response relationship for a drug is based on the relationship between dose, dose route, and drug exposure that is defined by the pharmacokinetics (ADME) of the drug (Fig. 2.1). Pharmacokinetics (PK) is defined loosely as what the body does to the drug and is comprised of the absorption, distribution, metabolism, and elimination (ADME) profile. A key principal in clinical pharmacology is studying how drug PK differs amongst populations. Initial PK studies in humans for most drugs are done in healthy, volunteer populations and the results extrapolated to and refined in patient populations.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Perry S. Reduction of toxicity in cancer chemotherapy. Cancer Res 1969; 29: 2319–25.
Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004; 30: 255–68.
Gustafson DL, Long ME, Zirrolli JA, et al. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother Pharmacol 2003; 52: 159–66.
Stowe CM, Plaa GL. Extrarenal excretion of drugs and chemicals. Annu Rev Pharmacol 1968; 8: 337–56.
Ludden TM. Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet 1991; 20: 429–46.
Wagner JG. Noncompartmental and System Analysis. Pharmacokinetics for the Pharmaceutical Scientist. Lancaster, PA: Technomic Publishing Company; 1993. p. 83–99.
DiStefano JJ, III. Noncompartmental vs. compartmental analysis: some bases for choice. Am J Physiol Regul Integr Comp Physiol 1982; 243: R1–6.
Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. A physiologically-based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res 2007; 13: 2768–76.
Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: macromolecule binding, metabolism and elimination in the context of a physiological model. J Pharm Sci 2002; 91: 1488–501.
Dedrick RL, Forrester DD, Cannon JN, El Dareer SM, Mellett LB. Pharmacokinetics of 1-d-arabinofuranosylcytosine (Ara-C) deamination in several species. Biochem Pharmacol 1973; 22: 2405–17.
Farris FF, King FG, Dedrick RL, Litterst CL. Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat. J Pharmacokinet Biopharm 1985; 13: 13–39.
Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. Methotrexate pharmacokinetics. J Pharm Sci 1971; 60: 1128–33.
Tsukamoto Y, Kato Y, Ura M, Horii I, Ishikawa T, Ishitsuka H, Sugiyama Y. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model. Biopharm Drug Dispos 2001; 22: 1–14.
Gustafson DL. Use of physiologically-based pharmacokinetic modeling coupled to Monte Carlo simulation to predict the pharmacokinetic interactions between doxorubicin and taxanes in human populations. Proc Am Assoc Cancer Res 2002; 43: 208.
Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445–79.
Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 1972; 5: 411–59.
Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods. Ann Pharmacother 2004; 38: 1907–15.
Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 1991; 32: 669–70.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Gustafson, D.L., Bradshaw-Pierce, E.L. (2011). Fundamental Concepts in Clinical Pharmacology. In: Garrett-Mayer, E. (eds) Principles of Anticancer Drug Development. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7358-0_2
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7358-0_2
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-7357-3
Online ISBN: 978-1-4419-7358-0
eBook Packages: MedicineMedicine (R0)